State of Tennessee Treasury Department Sells 2,564 Shares of Becton, Dickinson and Company (NYSE:BDX)

State of Tennessee Treasury Department reduced its position in Becton, Dickinson and Company (NYSE:BDXFree Report) by 2.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 102,712 shares of the medical instruments supplier’s stock after selling 2,564 shares during the quarter. State of Tennessee Treasury Department’s holdings in Becton, Dickinson and Company were worth $25,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Ontario Teachers Pension Plan Board boosted its position in shares of Becton, Dickinson and Company by 3.8% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 1,852,278 shares of the medical instruments supplier’s stock worth $451,641,000 after purchasing an additional 68,509 shares during the period. Sapient Capital LLC bought a new position in shares of Becton, Dickinson and Company during the fourth quarter worth $1,295,000. Vest Financial LLC boosted its position in shares of Becton, Dickinson and Company by 27.5% during the fourth quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock worth $25,115,000 after acquiring an additional 22,207 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Becton, Dickinson and Company by 69.4% during the fourth quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock worth $3,685,000 after acquiring an additional 6,190 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Becton, Dickinson and Company by 1.1% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 714,114 shares of the medical instruments supplier’s stock worth $174,122,000 after acquiring an additional 7,790 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of recent research reports. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, June 6th. Barclays increased their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Finally, The Goldman Sachs Group started coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average target price of $280.17.

Get Our Latest Stock Report on Becton, Dickinson and Company

Becton, Dickinson and Company Trading Down 0.4 %

BDX stock opened at $239.68 on Tuesday. The company has a market capitalization of $69.27 billion, a PE ratio of 52.79, a P/E/G ratio of 2.11 and a beta of 0.44. Becton, Dickinson and Company has a 12 month low of $224.00 and a 12 month high of $287.32. The firm’s 50-day moving average is $235.68 and its 200 day moving average is $238.03. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter last year, the firm posted $2.86 EPS. The firm’s revenue was up 4.6% compared to the same quarter last year. On average, research analysts anticipate that Becton, Dickinson and Company will post 13.03 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 1.59%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The disclosure for this sale can be found here. Insiders have sold a total of 8,597 shares of company stock worth $2,028,786 in the last three months. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Recommended Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.